Evidence map›Paper›PMID 40761300›Full record

ArticleClinical kidney journal2025

Long-term mortality and technique survival in peritoneal dialysis patients: a 25-year retrospective analysis in a single center.

Roberta Scarmignan, Gaetano Alfano, Niccolò Morisi, Francesco Fontana, Giacomo Mori, Marco Ferrarini, Camilla Ferri, Laura Tonelli, Giulia Ligabue, Riccardo Magistroni and 2 more

Abstract read
In one paragraph

Article in Clinical kidney journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Roberta ScarmignanSurgical, Medical and Dental Department of Morphological Sciences related to Transplant, Oncology and Regenerative Medicine (CHIMOMO), Section of Nephrology, University of Modena and Reggio Emilia, Modena, Italy.
Gaetano AlfanoNephrology, Dialysis and Kidney Transplant Unit, Azienda Ospedaliero Universitaria di Modena, Modena, Italy.ORCID https://orcid.org/0000-0003-0591-8622
Niccolò MorisiSurgical, Medical and Dental Department of Morphological Sciences related to Transplant, Oncology and Regenerative Medicine (CHIMOMO), Section of Nephrology, University of Modena and Reggio Emilia, Modena, Italy.
Francesco FontanaNephrology, Dialysis and Kidney Transplant Unit, Azienda Ospedaliero Universitaria di Modena, Modena, Italy.ORCID https://orcid.org/0000-0003-0762-0942
Giacomo MoriNephrology, Dialysis and Kidney Transplant Unit, Azienda Ospedaliero Universitaria di Modena, Modena, Italy.
Marco FerrariniSurgical, Medical and Dental Department of Morphological Sciences related to Transplant, Oncology and Regenerative Medicine (CHIMOMO), Section of Nephrology, University of Modena and Reggio Emilia, Modena, Italy.
Camilla FerriSurgical, Medical and Dental Department of Morphological Sciences related to Transplant, Oncology and Regenerative Medicine (CHIMOMO), Section of Nephrology, University of Modena and Reggio Emilia, Modena, Italy.
Laura TonelliSurgical, Medical and Dental Department of Morphological Sciences related to Transplant, Oncology and Regenerative Medicine (CHIMOMO), Section of Nephrology, University of Modena and Reggio Emilia, Modena, Italy.
Giulia LigabueSurgical, Medical and Dental Department of Morphological Sciences related to Transplant, Oncology and Regenerative Medicine (CHIMOMO), Section of Nephrology, University of Modena and Reggio Emilia, Modena, Italy.
Riccardo MagistroniSurgical, Medical and Dental Department of Morphological Sciences related to Transplant, Oncology and Regenerative Medicine (CHIMOMO), Section of Nephrology, University of Modena and Reggio Emilia, Modena, Italy.
Mariacristina GregoriniNephrology and Dialysis Unit, AUSL-IRCCS, Arcispedale S. Maria Nuova Reggio Emilia, Reggio Emilia, Italy.
Gabriele DonatiSurgical, Medical and Dental Department of Morphological Sciences related to Transplant, Oncology and Regenerative Medicine (CHIMOMO), Section of Nephrology, University of Modena and Reggio Emilia, Modena, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: We comprehensively assessed patient survival and the duration of peritoneal dialysis (PD) treatment over a 25-year period within our PD unit. Methods: We retrospectively evaluated 497 PD patients who initiated PD between 1996 and 2021. The cohort was divided into three distinct periods based on pivotal events, such as the introduction of more biocompatible dialysis solutions and the initiation of remote monitoring technologies. Kaplan-Meier survival assessments, Cox proportional hazards model and Gray subdistribution hazard model were employed to evaluate patient survival and PD-to-hemodialysis (HD) transfer. Results: The use of PD as the initial treatment increased significantly over the years. Mean age was 63.5 ± 15.7 years; 61% were male, and 61% had three or more comorbidities including hypertension (81%), dyslipidemia (66%), cardiovascular disease (56%) and diabetes (16%). The five-year mortality rate was 40%. Risk factors for mortality included continuous ambulatory peritoneal dialysis (CAPD) [hazard ratio (HR) = 2.63, 95% confidence interval (CI) 1.76-3.93; Conclusions: The study provides insights into the changing landscape of PD. Advances in PD solutions and remote monitoring have contributed to changes in PD outcomes and its increased adoption over the years. Given the observational nature of the study, caution is warranted in interpreting the association of both CAPD and RAASi with mortality.

Indexed as

mortality rateperitoneal dialysistechnique failuretransition to hemodialysis

Identifiers

PMID40761300
PMCPMC12319534

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.